Please login to the form below

Not currently logged in
Email:
Password:

Huntington's disease

This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.

Sage’s postpartum depression treatment Zulresso gains US approval

Sage’s postpartum depression treatment Zulresso gains US approval

Today’s approval of Zulresso represents a game-changing approach to treating PPD,” said Dr. ... cognition-related disorders such as Huntington’s disease, both of which are in phase 1 testing.

Latest news

  • Sage raises $575m ahead of FDA review date for Zulresso Sage raises $575m ahead of FDA review date for Zulresso

    of a possible US launch for Zulresso, says the company’s SEC prospectus for the fundraising. ... as Huntington’s disease, both of which are in phase 1 testing.

  • Roche buys gene therapy specialist Spark for $4.3bn Roche buys gene therapy specialist Spark for $4.3bn

    Also in Spark’s pipeline is SPK-7001 for choroideremia in phase 1/2, while two other candidates - SPK-3006 for Pompe disease and SPK-1001 for CLN2 disease – are due ... Spark has additional preclinical programmes in Huntington's disease and Stargardt

  • Teva will have to endure revenue 'trough' in 2019 Teva will have to endure revenue 'trough' in 2019

    fourth quarter to $4.6bn, although Schultz’s cost-cutting drive helped trim the company’s net loss in the period to $2.9bn from $11.6bn a year earlier. ... To reverse the trend, Teva needs new products such as migraine prevention therapy Ajovy

  • UniQure cleared to start Huntington gene therapy trial UniQure cleared to start Huntington gene therapy trial

    AMT-130 becomes the first AAV-based therapy approved for trials in Huntington’s disease. ... The FDA has given UniQure the nod to start a gene therapy trial in Huntington’s disease, the first for the company involving a central nervous system disease.

  • Ionis and Roche gain PRIME status for Huntingdon’s disease candidate Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

    More good news for Ionis after first drug approval. Ionis and Roche’s pipeline drug for Huntingdon’s disease has been granted special ‘PRIME’ status by the European Medicines Agency (EMA). ... Ionis' C Frank Bennett. "PRIME designation for

More from news
Approximately 5 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease. ... It’s hoped it could be a big step in treatment for the genetically-inherited and rare wasting disease.

  • Deal Watch May 2016 Deal Watch May 2016

    Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... disease late last year, Bayer announced another gene editing pact this month with ERS Genomics.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease. ... Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • VCCP Health

    Not only do they bring experience working on Rx accounts such as the immunology biosimilar portfolio for Novartis, but passion and expertise for animal health, disease awareness and charity work. ... 2016, Echoes of the past, Huntington's Disease (Teva).

  • Use of biomarkers in marketing

    pathway.  . When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’s disease and Alzheimer’s; these are prognosis biomarkers. ... A crowded market of biologics treating a chronic disease with very

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics